These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 37395182)
1. Baseline albumin-bilirubin score: a predictor for HBeAg clearance in patients with chronic hepatitis B after nucleos(t)ide analogue treatment. Zhang Y; Gu Y; Yin S; Wang J; Zhang Z; Liu Y; Chen Y; Zhan J; Xue R; Yan X; Zhang S; Ding W; Chen Y; Li J; Huang R; Wu C Eur J Gastroenterol Hepatol; 2023 Sep; 35(9):1023-1029. PubMed ID: 37395182 [TBL] [Abstract][Full Text] [Related]
2. Albumin-bilirubin score is associated with response to pegylated interferon and nucleos(t)ide analogues in chronic hepatitis B patients. Xun Z; Liu C; Yu QQ; Lin JP; Huang JL; Yang TW; Wu WN; Wu SH; Ou QS Clin Chim Acta; 2020 Mar; 502():120-127. PubMed ID: 31891671 [TBL] [Abstract][Full Text] [Related]
3. Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues. Wang Y; Liao H; Deng Z; Liu Y; Bian D; Ren Y; Yu G; Jiang Y; Bai L; Liu S; Liu M; Zhou L; Chen Y; Duan Z; Lu F; Zheng S J Viral Hepat; 2022 Jun; 29(6):420-431. PubMed ID: 35274400 [TBL] [Abstract][Full Text] [Related]
4. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. Xue Y; Zhang M; Li T; Liu F; Zhang LX; Fan XP; Yang BH; Wang L World J Gastroenterol; 2021 Apr; 27(14):1497-1506. PubMed ID: 33911470 [TBL] [Abstract][Full Text] [Related]
5. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492 [TBL] [Abstract][Full Text] [Related]
6. A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice. Geng M; Li Y; Gao F; Sun L; Yang X; Wang R; Chen J; Zhang Q; Wan G; Wang X Int J Infect Dis; 2017 Sep; 62():18-25. PubMed ID: 28669850 [TBL] [Abstract][Full Text] [Related]
7. A novel nomogram for predicting HBeAg seroclearance in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues. Gu Y; Zhang Y; Zhang Z; Wang J; Zhang Q; Zhang S; Liu Y; Liu J; Xia J; Yan X; Li J; Liu X; Huang R; Wu C Ann Hepatol; 2024; 29(1):101151. PubMed ID: 37704066 [TBL] [Abstract][Full Text] [Related]
8. [A retrospective follow-up study of prolonged nucleos(t)ide analogue and interferon combination therapy in HBeAg-positive chronic hepatitis B patients]. Yu SL; Guo CY Zhonghua Gan Zang Bing Za Zhi; 2013 Apr; 21(4):267-70. PubMed ID: 24021787 [TBL] [Abstract][Full Text] [Related]
9. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status. Liu F; Liu ZR; Li T; Liu Y; Zhang M; Xue Y; Zhang LX; Ye Q; Fan XP; Wang L J Dig Dis; 2018 Sep; 19(9):561-571. PubMed ID: 30098114 [TBL] [Abstract][Full Text] [Related]
10. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes. Van Hees S; Bourgeois S; Van Vlierberghe H; Sersté T; Francque S; Michielsen P; Sprengers D; Reynaert H; Henrion J; Negrin Dastis S; Delwaide J; Lasser L; Decaestecker J; Orlent H; Janssens F; Robaeys G; Colle I; Stärkel P; Moreno C; Nevens F; Vanwolleghem T; Aliment Pharmacol Ther; 2018 Apr; 47(8):1170-1180. PubMed ID: 29498078 [TBL] [Abstract][Full Text] [Related]
11. Early Serum HBsAg Drop Is a Strong Predictor of HBeAg Seroconversion and HBsAg Loss to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients with Prior Nucleos(t)ide Analogue Exposure. Chen Q; Zhang J; Huang J; Quan B; Wu X; Deng S; Han W Med Sci Monit; 2019 Jun; 25():4665-4674. PubMed ID: 31230063 [TBL] [Abstract][Full Text] [Related]
12. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653 [TBL] [Abstract][Full Text] [Related]
13. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment. Hao R; Xiang K; Peng Y; Hou J; Sun J; Li Y; Su M; Yan L; Zhuang H; Li T Infect Genet Evol; 2015 Jul; 33():261-8. PubMed ID: 25976382 [TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833 [TBL] [Abstract][Full Text] [Related]
15. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F; Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133 [TBL] [Abstract][Full Text] [Related]
16. Baseline and on-treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals. Hwang SY; Yoo SH; Chang HY; Kim S; Lee JI; Lee KS; Cho YY; Joon KH; Lee HW J Viral Hepat; 2023 Jan; 30(1):39-45. PubMed ID: 36321949 [TBL] [Abstract][Full Text] [Related]
17. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy. Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649 [TBL] [Abstract][Full Text] [Related]
18. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice. Lin B; Ha NB; Liu A; Trinh HN; Nguyen HA; Nguyen KK; Ahmed A; Keeffe EB; Garcia RT; Garcia G; Nguyen MH J Gastroenterol Hepatol; 2013 May; 28(5):855-60. PubMed ID: 23278507 [TBL] [Abstract][Full Text] [Related]
19. Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs. Li T; Liu F; Zhang L; Ye Q; Fan X; Xue Y; Wang L Saudi J Gastroenterol; 2018; 24(1):30-36. PubMed ID: 29451182 [TBL] [Abstract][Full Text] [Related]
20. Predictors of HBeAg seroconversion after long-term nucleos(t)ide analogues treatment for chronic hepatitis B: a multicenter study in real clinical setting. Yu W; Wang Y; Shen C; Ji R; Zhang L; Zhao X; Su M; Zhang Y; He W; Cao J; Hao Y; Chen S; Zhao C Braz J Infect Dis; 2017; 21(3):213-218. PubMed ID: 28351603 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]